A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2017-09-08
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects
with previously treated solid tumors. Study includes a dose escalation phase and expansion
phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers,
and efficacy.